News 
Market Data 
Discover
Replies to post #3074032 on BB's Stock Haven
07/30/13 3:39 PM
www.sec.gov/Archives/edgar/data/1125280/000101376212000880/form10k.htm
In consideration for the grant of the exclusive license, the licensee agreed to pay us an up-front license fee of $1,000,000 payable as follows: (i) an initial installment of One Hundred Fifty Thousand Dollars ($150,000) upon execution of the agreement; (ii) One Hundred Thousand Dollars ($100,000) within three (3) days of the completion of the Lab Equipment (as defined in the agreement) having been delivered and installed (in accordance with applicable cGMP’s and cGTP’s of the US FDA) and the Lab Technician (as defined in the agreement) for the initial Laboratory Facility (as defined in the Thailand Agreement) having completed training; and (iii) the balance of Seven Hundred Fifty Thousand Dollars ($750,000) to be placed in escrow with counsel for the Company upon the payment of the second installment, with such funds to be held in escrow for a period of ninety (90) days, with such funds to be released upon satisfaction by the parties that the Lab Equipment is in working order and the Lab Technician has been adequately trained.
Thursday, June 20, 2013
www.wnd.com/markets/news/read/20356239/intellicell_biosciences_announces_the_licensing_of_its_proprietary_patent
Intellicell Biosciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC); (“Intellicell”) or the (“Company”), Intellicell has licensed its proprietary, patent, pending technology for the manufacture of stromal vascular fraction from adipose tissue to Cell-Innovations, Pty Limited a company headquartered in Sydney, Australia. The license calls for a one-time payment of $700,000 and a royalty stream of 12 ½ % of net of sales.
Intellicell’s process is a patent-pending non-enzymatic method for deriving stromal vascular fraction from 60cc’s of adipose tissue. This process dramatically increases the yield in manufacturing stromal vascular fraction compared to the present enzymatic methods in use today. Intellicell’s process generates between half billion - 1.4 billion SVFC cells from 60 ccs from a patient’s own adipose tissue. This is approximately 10-20 times greater than enzyme based methods. Dr. Steven Victor, CEO, said “we are extremely excited about our licensing partnership with Cell-Innovations, Inc. We believe they are one of the best positioned companies to market the Intellicell technology in Australia & New Zealand.
Cell-Innovations is an Australian company headquartered in Sydney servicing the burgeoning regenerative medicine market by providing innovative IntelliCell technology to the Australian and New Zealand marketplace. We believe that IntelliCell technology will be a “game-changer” in the regenerative medicine field making available stromal vascular fraction (SVF) treatment to the public. Cell-Innovations CEO is Dr. Wayne Thomas BSc PhD a founder of Australian Cell Technologies, a company introducing regenerative cellular products to the veterinary market. Dr. Thomas has 25 years experience in cell biology and developed kits for adipose SVF for the veterinary market. Dr. Thomas’ research contributions has been recognized by many publications and book chapters, and is a reviewer for both national and international granting bodies and journals; and, will be a scientific advisor for IntelliCell. Dr Ralph Bright MB ChB FFMACC is a director with Cell-Innovations and is a pioneer in stromal vascular fraction treatments in Australia, a Fellow and Member of many cosmetic medicine organizations including the Cosmetic Physicians Society of Australasia and the Australian College of Cosmetic Surgery. Dr Bright has been treating patients with adipose SVF since 2009 for osteoarthritis and degenerative neurological disease and is one of the most experienced physicians in Australia in the use of adipose SVF. “Cell-Innovations and IntelliCell will assist Macquarie Stem Cells to establish ‘Intellicell Centers of Excellence’ where doctors can treat their patient”
